Clinical trials
Liver Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting liver cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,775 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03753243RecruitingPhase 2
Pembrolizumab and hormone blocker before prostate surgery
This Phase 2 trial studies whether pembrolizumab plus a hormone “androgen axis” blocker taken before prostate surgery can improve outcomes for people with high-risk, non-metastatic prostate cancer. It’s designed for patients who are planning prostate removal with an extended lymph node dissection.
Portland, OregonAges 18 years+ - NCT04161664RecruitingPhase 2
Chemo for metastatic vulvar cancer with carboplatin and paclitaxel
This trial studies how well carboplatin plus paclitaxel chemotherapy works for vulvar squamous cell cancer that has spread. It may help shrink tumors and control cancer growth in people who are not able to be fully treated with local surgery.
AmsterdamAges 18 years+ - NCT05501353Recruiting
Study tumor biomarkers in recurrent metastatic colon cancer
This study looks for blood/tumor signals (“biomarkers”) that may help predict outcomes in people whose colorectal cancer returns and spreads after surgery. It mainly helps researchers understand who may do better or worse, which can guide future care.
Hangzhou, ZhejiangAges 18–99 - NCT05851014RecruitingPhase 3
GB491 plus letrozole for HR+ HER2- advanced breast cancer
This Phase 3 study tests whether GB491 used together with letrozole works better for hormone receptor–positive and HER2-negative advanced breast cancer. You may be eligible if you have not had certain prior cancer treatments and your health tests are within safe limits.
Bengbu, AnhuiAges 18–75 - NCT05856383Recruiting
HER2-positive metastatic breast cancer drug combination study
This trial tests whether inetetamab combined with pyrotinib and vinorelbine works better and is safe for adults with HER2-positive advanced breast cancer. You may be considered if standard options have not removed the cancer with surgery and your body can handle chemotherapy and HER2-targeting medicines.
Hangzhou, ZhejiangAges 18 years+ - NCT05795335Recruiting
Testing CDK4/6 medicines for advanced hormone-positive breast cancer
This trial studies how CDK4/6 medicines fit into treatment for people with advanced hormone receptor–positive breast cancer that cannot be cured with surgery or radiation. It may help doctors understand the best way to use these medicines for disease that has returned or spread.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05209243Recruiting
Treating limited-spread prostate cancer with radiation plus hormone therapy
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
MadridAges Any age - NCT05251883Recruiting
Study of data from metastatic ovarian cancer using multiple tests
This study looks at metastatic ovarian cancer by analyzing many types of patient data (from “multi-omics,” which means different kinds of lab and biological information). It may help doctors better understand the disease and improve future care.
Guangzhou, GuangdongAges 18 years+ - NCT04020575RecruitingPhase 1
CAR T cells made from your blood for advanced breast cancer
This Phase 1 trial tests CAR T cells made from your own immune cells to target advanced breast cancer. The cells are designed to recognize a specific cancer marker (called MUC1*), with the goal of shrinking tumors or keeping them under control.
Duarte, CaliforniaAges 18 years+ - NCT05753839Recruiting
Testing surgery plus immunotherapy for metastatic kidney cancer
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
SeoulAges 18 years+ - NCT05869474Recruiting
Iodine seed implant plus chemotherapy for metastatic pancreatic cancer
This trial studies whether placing iodine-125 radioactive seeds during a procedure, along with chemotherapy, can improve outcomes for people with pancreatic cancer that has spread to other organs. It aims to test a treatment that targets the tumor area while systemic chemotherapy works throughout the body.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05983783RecruitingPhase 3
Testing two drug combinations for advanced prostate cancer
This trial compares two combinations of drugs for men with metastatic hormone-sensitive prostate cancer that has a high tumor burden. One group gets rezvilutamide plus hormone therapy and chemotherapy, while the other gets rezvilutamide plus hormone therapy alone. The goal is to see which is more effective and safe.
Nanjing, JiangsuAges 40–80 - NCT06043973RecruitingPhase 3
Almonertinib plus anlotinib for first-line advanced lung cancer
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
Jinan, ShandongAges 18–75 - NCT05502913RecruitingPhase 2
Fecal transplant plus cancer immunotherapy for lung cancer
This trial studies whether giving a fecal microbiota transplant (a stool-based sample from a carefully screened donor) alongside immune checkpoint inhibitors can improve outcomes in people with lung cancer. It aims to change the gut bacteria to help the immune system work better against the cancer.
BeershebaAges 18 years+ - NCT05832827RecruitingPhase 2
First treatment combo for thymic cancer using pembrolizumab plus drugs
This Phase 2 study tests a first (initial) treatment combination of pembrolizumab with three other drugs (carboplatin, paclitaxel, and lenvatinib) for advanced or recurrent thymic carcinoma. It aims to shrink tumors and improve control of the cancer when standard chemotherapy has not yet been tried for your situation.
Chūō, TokyoAges 18 years+ - NCT06176885RecruitingPhase 2
Immunotherapy plus chemo and targeted therapy for MSS colorectal cancer
This trial tests adding immunotherapy to standard chemotherapy and targeted therapy for people with metastatic colorectal cancer that is MSS (microsatellite stable) and cannot be removed with surgery. It aims to see if this combination helps shrink tumors and improve outcomes.
Jinhua, ZhejiangAges 18–75 - NCT07871110RecruitingPhase 2
New pill combined with hormone therapy for advanced prostate cancer
This study tests a new pill (TT00420) taken with standard hormone therapy for prostate cancer that has spread and is no longer responding to initial hormone treatment. The goal is to see if the combination can help slow the cancer's growth and is safe.
Fuzhou, FujianAges 18 years+ - NCT06123494RecruitingPhase 3
A trial of SHR-A1811 for HER2-positive gastric cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT02215889RecruitingPhase 1/Phase 2
Partial liver transplant for colon or rectal cancer spread to liver
This trial tests whether transplanting part of the liver can help people with colon or rectal cancer that has spread to the liver but cannot be removed with surgery. It also aims to make sure the cancer is limited mainly to the liver and that you are healthy enough for major treatment.
OsloAges 18 years+ - NCT06249750RecruitingPhase 2
Heat shock therapy for castration-resistant prostate cancer
This trial tests a near-infrared whole-body heat shock technique to treat prostate cancer that no longer responds to hormone therapy. It aims to see if this heat-based approach can help control the cancer.
Hangzhou, ZhejiangAges 18–90 - NCT06254690RecruitingPhase 2
Pyrotinib dosing study for HER2-positive advanced breast cancer
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
Nanjing, JiangsuAges 18–70 - NCT07863986Recruiting
Studying response to lutetium therapy for advanced prostate cancer
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
KaunasAges 18 years+ - NCT06270017RecruitingPhase 1/Phase 2
Zebrafish Avatars for Colon Cancer Treatment
This trial uses tiny zebrafish to grow a piece of your tumor and test which treatments might work best for you. It is for patients with colon cancer who are scheduled for surgery to remove their tumor.
Linköping, Östergötland CountyAges 18 years+ - NCT07860528Recruiting
High-dose brachytherapy for prostate cancer that has returned
This trial tests a type of radiation therapy called high-dose-rate brachytherapy, which is given to men whose prostate cancer has come back after their first treatment. It aims to control the cancer while keeping side effects low.
Benidorm, AlicanteAges 18 years+
Hear when a new Liver Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,775 recruiting liver cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Locally Advanced or Metastatic)
- Locally Advanced Rectal Cancer
- Locally Advanced Cervical Cancer
- Locally Advanced Breast Cancer
- Locally Advanced or Metastatic Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.